Responsive image

AstraZeneca Says Rare Disease Drug Shows Improvements in Inherited Bone Disorder

On Monday, AstraZeneca Plc (NYSE:AZN) shared detailed results from the HICKORY Phase 3 trial of efzimfotase alfa (ALXN1850) for hypophosphatasia (HPP), an inherited metabolic disease caused by deficient activity of the enzyme alkaline phosphatase (ALP), which helps in building healthy bones and supporting proper muscle function. HPP is characterized by defective mineralization (the process that […]
Responsive image

Humana Stock Hits 52-Week High After Medicare Ratings Boost

Humana Inc. (NYSE:HUM) said Friday that its 2027 Medicare Advantage Star Ratings improved significantly, with 95% of members enrolled in plans earning at least four stars from the Centers for Medicare and Medicaid Services (CMS). Additionally, 42% of its Medicare Advantage members are enrolled in plans rated 4.5 stars or higher, reflecting broad improvements across […]
Responsive image

SpaceX Reclaims its Debut Close, but Options Are Pricing a Slow Grind Ahead

Space Exploration Technologies Corp. (NASDAQ:SPCX) is back above its first-day close, but the options market suggests traders shouldn’t expect a quick run back to the stock’s June highs. SpaceX shares rose 0.49% Tuesday, on top of Monday’s roughly 8% gain to $171.09, to mark their highest close since mid-June. The stock is up nearly 50% […]
Responsive image

Peter Thiel Says U.S. AI Demand Is Booming, but Cathie Wood Is Trimming Palantir

Cathie Wood-led Ark Invest trimmed its position in Palantir Technologies Inc. (NASDAQ:PLTR) on Thursday, as the artificial intelligence software company’s stock continued to attract investor attention after a strong third quarter. The Palantir Technologies Trade ARK Invest sold 14,970 Palantir shares through its ARK Autonomous Technology & Robotics ETF (NYSE:ARKQ) and another 5,835 shares through […]
Responsive image

Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows…

Editor’s note: The title of this article has been updated Novo Nordisk A/S (NYSE:NVO) announced on Tuesday new real-world evidence demonstrating that escalating semaglutide dosage reduces major adverse cardiovascular events compared to switching to Eli Lilly and Co.’s (NYSE:LLY) tirzepatide. Real-World Data Highlights Cardiovascular Benefits The retrospective analysis evaluated 636,525 adults with type 2 diabetes […]
Responsive image

Bullish: Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Mizuho analyst Vijay Rakesh initiated coverage on Tower Semiconductor Ltd (NASDAQ:TSEM) with an Outperform rating and announced a price target of $300. Tower Semiconductor […]

Newsletter

Top 3 Real Estate Stocks That May Plunge In Q1

January 27, 2025

As of Jan. 27, 2025, three stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices […]
Read More